Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics

Dwivedi, Ruby; Pandey, Rahul; Chandra, Shaleen; Mehrotra, Divya

doi:10.2217/imt-2022-0238

Cited by 6 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it should be tested whether FoxO1 overexpression or activation suppresses or reverses the pathogenesis of OSCC. Several therapeutic options have been developed for the treatment of OSCC ( 44 ). Nonetheless, complete recovery from OSCC is not easy.…”

Section: Discussionmentioning

confidence: 99%

Anti‑tumor properties of FoxO1 in YD‑9 oral squamous cell carcinoma cells

et al. 2023

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is a tumor with a poor prognosis and a high recurrence rate. Despite its high annual incidence worldwide, appropriate therapeutic strategies have not yet been developed. Consequently, the 5-year survival rate for OSCC is low when advanced stages or recurrence is diagnosed. Forkhead transcriptional factor O1 (FoxO1) is a key mediator for maintaining cellular homeostasis. FoxO1 can function as a tumor suppressor as well as an oncogene depending on the cancer type. Therefore, the precise molecular functions of FoxO1 need to be validated, considering intracellular factors and the extracellular environment. To the best of our knowledge, however, the roles of FoxO1 in OSCC have not yet been defined. The present study examined FoxO1 levels under pathological conditions (oral lichen planus and oral cancer) and selected an appropriate OSCC cell line (YD-9). Crispr/Cas9 was used to generate FoxO1-deficient YD-9 cells in which the protein levels of phospho ERK and phospho STAT3 were upregulated, promoting cancer proliferation and migration. In addition, FoxO1 reduction increased the levels of the cell proliferation markers phospho H3 (Ser10) and PCNA. FoxO1 loss significantly reduced cellular ROS levels and apoptosis in YD-9 cells. Collectively, the present study demonstrated that FoxO1 exerted an anti-tumor effect by suppressing proliferation and migration/invasion but promoting oxidative stress-linked cell death in YD-9 OSCC cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti‑tumor properties of FoxO1 in YD‑9 oral squamous cell carcinoma cells

et al. 2023

View full text Add to dashboard Cite

show abstract

“…These cells are cultivated in a laboratory setting, loaded with specific tumor antigens, and subsequently administered to the patients through regular injections [ 16 ]. Presently, DC vaccines have found extensive application in treating various tumors, including neurospoagioma [ 17 – 19 ]. This review comprehensively outlines the immunomodulatory effects and associated mechanisms of DC vaccines in the context of neurospoagioma.…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine

Qian,

Liu,

Zheng

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

Neurospagioma, arising from different glial cells such as astrocytes, oligodendrocytes, and ependymal cells, stands as the prevalent intracranial tumor within the central nervous system. Among its variants, glioblastoma (GBM) represents the most aggressive form, characterized by a notably high occurrence rate and a discouragingly low survival prognosis. The formidable challenge posed by glioblastoma underscores its critical importance as a life-threatening ailment. Currently, clinical approaches often involve surgical excision along with a combination of radiotherapy and chemotherapy. However, these treatments frequently result in a notable recurrence rate, accompanied by substantial adverse effects that significantly compromise the overall prognosis. Hence, there is a crucial need to investigate novel and dependable treatment strategies. Dendritic cells (DCs), being specialized antigen-presenting cells (APCs), hold a significant position in both innate and adaptive immune responses. Presently, DC vaccines have gained widespread application in the treatment of various tumors, including neurospoagioma. In this review, we summarize the immunomodulatory effects and related mechanisms of DC vaccines in neurospoagioma as well as the progress of clinical trials to propose possible challenges of DC vaccines and new development directions.

show abstract

“… 8 By utilizing the potential of the immune system, immunotherapy seeks to enhance the body's inherent ability to combat cancer cells. 9 , 10 Using these therapies, the immune system is stimulated or manipulated so that cancer cells can be recognized and destroyed more effectively by the immune system. In addition to having shown remarkable success in treating some types of cancer, immunotherapy has proven to be variable in its efficiency among different patients, and research continues to be conducted to improve its results.…”

Section: Introductionmentioning

confidence: 99%

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Lotfalizadeh,

Sadr,

Morovati

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundRecently, immunotherapy has become very hopeful for cancer therapy. Cancer treatment through immunotherapy has excellent specificity and less toxicity than conventional chemoradiotherapy. Pathogens have been used in cancer immunotherapy for a long time. The current study aims to evaluate the possibility of Toxoplasma gondii (T. gondii) as a probable treatment for cancers such as melanoma, breast, ovarian, lung, and pancreatic cancer.Recent findingsNonreplicating type I uracil auxotrophic mutants of T. gondii can stimulate immune responses against tumors by reverse immunosuppression at the cellular level. T. gondii can be utilized to research T helper 1 (Th1) cell immunity in intracellular infections. Avirulent T. gondii uracil auxotroph vaccine can change the tumor's immunosuppression and improve the production of type 1 helper cell cytokines, i.e., Interferon‐gamma (IFN‐γ) and Interleukin‐12 (IL‐12) and activate tumor‐related Cluster of Differentiation 8 (CD8+) T cells to identify and destroy cancer cells. The T. gondii profilin protein, along with T. gondii secreted proteins, have been found to exhibit promising properties in the treatment of various cancers. These proteins are being studied for their potential to inhibit tumor growth and enhance the effectiveness of cancer therapies. Their unique mechanisms of action make them valuable candidates for targeted interventions in ovarian cancer, breast cancer, pancreatic cancer, melanoma, and lung cancer treatments.ConclusionIn summary, the study underscores the significant potential of harnessing T. gondii, including its diverse array of proteins and antigens, particularly in its avirulent form, as a groundbreaking approach in cancer immunotherapy.

show abstract

Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics

Cited by 6 publications

References 54 publications

Anti‑tumor properties of FoxO1 in YD‑9 oral squamous cell carcinoma cells

Anti‑tumor properties of FoxO1 in YD‑9 oral squamous cell carcinoma cells

Dendritic cell therapy for neurospoagioma: Immunomodulation mediated by tumor vaccine

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Contact Info

Product

Resources

About